MJ, J., KW, M., B, N., R, A., GL, B., BM, B., . . . investigators, C. s. (2017). The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Citación estilo ChicagoMJ, Jardine, et al. The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. 2017.
Cita MLAMJ, Jardine, et al. The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. 2017.
Precaución: Estas citas no son 100% exactas.